Table 2
From the following article
Complement-targeted therapeutics
Daniel Ricklin & John D Lambris
Nature Biotechnology 25, 1265 - 1275 (2007) Published online: 7 November 2007
doi:10.1038/nbt1342
Table 2. Complement therapeutics in pre-clinical development
| Product (company) | Activity | Stage of development |
|---|---|---|
aCurrently, there are no complement-specific serine protease inhibitors listed in the pipelines of pharmaceutical companies. | ||
bOphthalmology compounds are developed further by Jerini Ophthalmic. | ||
| Protease inhibitors (A) | ||
| Factor D inhibitorsa (BCX1470 etc.) | Small molecule serine protease inhibitors | Mostly discontinued (due to lack of specificity and/or short half-life) |
| Soluble complement regulators (B) | ||
| sCR1-sLex/TP-20 (Avant Immunotherapeutics) | sCR1 with sLex-rich glycosylation to target sites of inflammation | Development/preclinical (stroke, heart attack) |
| Mirococept (Inflazyme Pharmaceuticals) | sCR1 with lipopeptide membrane linker | Preclinical (AMI, inflammatory diseases) |
| Therapeutic antibodies (C) | ||
| TNX-234 (Tanox) | Humanized antibody against factor D | Preclinical (wet AMD) |
| TNX-558 (Tanox) | Humanized antibody against C5a | Development/preclinical (inflammatory diseases) |
| TA106 (Taligen Therapeutics) | Antibody against factor B | Development/preclinical |
| Neutrazumab (G2 Therapies) | Antibody blocking the C5a receptor | Development/preclinical (RA, stroke) |
| Anti-properdin (Novelmed Therapeutics) | Antibody against properdin | Development/preclinical |
| HuMax-CD38 (Genmab A/S) | Humanized anti-CD38 mAb that triggers complement | Preclinical studies (cancer, multiple myeloma) |
| Complement component inhibitors (D) | ||
| ARC1905 (Archemix) | Aptamer-based C5 inhibitor (PEG-ylated) | Preclinical (AMD) |
| Receptor antagonists (E) | ||
| JPE-1375, JSM-7717 (Jerinib) | Small molecule/peptidomimetic antagonists for C5a receptor | Preclinical (inflammation, renal and ocular diseasesb) |
